Indivior Pharmaceuticals, Inc. reported $1.33B of revenue over the trailing twelve months, +13% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.33B (to Q2 2026). Net income: $355M, trailing twelve months to Q2 2026. Free cash flow: −$111M, trailing twelve months to Q2 2026. Operating margin: 32%, trailing twelve months to Q2 2026.

INDVIndivior Pharmaceuticals, Inc.

Healthcare

$35.84+59% 1Y

$35.84

$22.7352 weeks$41.47

INDV as reported

Indivior Pharmaceuticals, Inc. reported $1.33B of revenue over the trailing twelve months, +13% on the year before. 11 reported series are charted on this page, each one as filed.

$1.33B

Revenue, trailing twelve months · to Q2 2026 · +13% against the twelve months before

Net income: $355M
Net income · +229% year on year · trailing twelve months to Q2 2026
Free cash flow: −$111M
Free cash flow · −164% year on year · trailing twelve months to Q2 2026
Operating margin: 32%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for INDV, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.33B	+13%	Q2 2026
Net income	$355M	+229%	Q2 2026
EPS	$2.79	+232%	Q2 2026
Gross margin	82%	n/a	Q2 2026
Operating margin	32%	n/a	Q2 2026
Net margin	26%	n/a	Q2 2026
ROE	−155%	n/a	Q2 2026
ROA	19%	n/a	Q2 2026
ROIC	371%	n/a	Q2 2026
Free cash flow	−$111M	−164%	Q2 2026
P/E	12.8	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.